NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

MapLight Therapeutics, Inc. (MPLT) Stock Analysis

MapLight Therapeutics, Inc. (MPLT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

MPLT

$8.16

−$0.08 (−0.97%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MPLT with… →

MPLT Key Statistics

As of Oct 21, 2026
Trading
Open
$8.21
Previous Close
$8.24
Day's Range
8.00–8.58
52-Week Range
7.46–40.43
Volume
343.84K
Valuation
Market Cap
$453.50M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−6.25
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$161.15M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
52.85M
1-Year Return
−55.51%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
817.21K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, MPLT closed at $8.16, −55.51% over 1 year.

MapLight Therapeutics, Inc. (MPLT) has a market capitalization of $453.50M.

MPLT Stock Return by Calendar Year

MapLight Therapeutics, Inc. (MPLT) return since Oct 2025: what $10,000 became

1 year
$10,000 $4,449
−55.51%

If you had invested $10,000 in MapLight Therapeutics, Inc. (MPLT) at the close on October 27, 2025, the earliest close on record here, it would have been worth $4,449 at the close on October 21, 2026: −55.51% in total, −55.51% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−53.54%
2025 (partial year)−4.23%

As of October 21, 2026.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

MapLight Therapeutics, Inc. (MPLT) is capitalised at $453.50M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 133.

The most recent close on file for MPLT is $8.16, dated October 21, 2026. That is −$0.08 (−0.97%) against the previous close. The 52-week range on file runs from $7.46 to $40.43. The latest close sits 9.38% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $161.15M. Trailing earnings per share are −6.25.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Annualized volatility over the trailing 1 year is 113.39%. The trailing one-year total return is −55.51%.

Growth & Income

The record shows no dividend for MPLT.

So far in 2026 the total return is −53.54%.

Peer Comparison

MapLight Therapeutics, Inc. (MPLT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
MapLight Therapeutics, Inc. MPLT $453.50M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. MapLight Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.

Visit website →